Phase I study of human recombinant biglycan (TVN-102)

Trial Profile

Phase I study of human recombinant biglycan (TVN-102)

Phase of Trial: Phase I

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs TVN 102 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Sep 2016 New trial record
    • 16 Aug 2016 A planned IND submission is on track and phase I clinical trials will be initiated in 2017, according to Tivorsan pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top